Dr. Shore on Radium-223 Patient Considerations

Neal D. Shore, MD
Published: Monday, Aug 26, 2013

Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Myrtle Beach, discusses patient considerations following treatment with radium-223 for bone metastases from prostate cancer.

Radium-223 gets into bone lesions in a matter of minutes, Shore says. Radium-223 is not metabolized by a patient's kidneys or liver, it is simply decayed into fecal matter. A patient is at no real risk following infusion, but should avoid contact with fecal matter.
 
Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Myrtle Beach, discusses patient considerations following treatment with radium-223 for bone metastases from prostate cancer.

Radium-223 gets into bone lesions in a matter of minutes, Shore says. Radium-223 is not metabolized by a patient's kidneys or liver, it is simply decayed into fecal matter. A patient is at no real risk following infusion, but should avoid contact with fecal matter.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x